AnaptysBio
ANAB
Market cap $1.03B

33.98 USD

-1.05

3%

At close Oct 4, 4:00 PM EDT

After hours

33.98

+0.00

0%

1 day

-3.00%

5 days

7.57%

1 month

-8.48%

3 months

37.29%

6 months

59.53%

Year to date

56.59%

1 year

84.07%

5 years

2.26%

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 117

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

12% more call options, than puts

Call options by funds: $794K | Put options by funds: $707K

11% more capital invested

Capital invested by funds: $671M [Q1] → $746M (+$74.3M) [Q2]

2% more funds holding

Funds holding: 131 [Q1] → 133 (+2) [Q2]

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

2% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 44

2.49% less ownership

Funds ownership: 111.42% [Q1] → 108.93% (-2.49%) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$30

12%

downside

Avg. target

$54

60%

upside

High target

$75

121%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

Wedbush David Nierengarten 47% 1-year accuracy 29 / 62 met price target	24%upside $42	Outperform Reiterated	26 Sept 2024
Truist Securities John Lee 0 / 0 met price target	12%downside $30	Hold Maintained	15 Aug 2024
HC Wainwright & Co. Emily Bodnar 25% 1-year accuracy 26 / 106 met price target	62%upside $55	Buy Reiterated	14 Aug 2024
JP Morgan Anupam Rama 43% 1-year accuracy 20 / 47 met price target	121%upside $75	Overweight Maintained	7 Aug 2024
HC Wainwright & Co. Emily Bodnar 25% 1-year accuracy 26 / 106 met price target	62%upside $55	Buy Reiterated	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Anaptys Announces Participation in September Investor Conferences

The Motley Fool

Why AnaptysBio Was Such a Healthy Stock This Week

The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.

Why AnaptysBio Was Such a Healthy Stock This Week

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Investors Business Daily

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $1.50 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™